Assessment of Interactions Between Intravenous Methamphetamine and Modafinil - 1
NCT ID: NCT00265278
Last Updated: 2017-01-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
16 participants
INTERVENTIONAL
2005-03-31
2006-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase 2, Multi-Center Trial of Modafinil for Methamphetamine Dependence
NCT00520286
A Phase 1 Parallel-Group, Double-Blind, Placebo-Controlled Cardiovascular and Behavioral Study Assessing Interactions Between Single Doses of Oral Reserpine and Intravenous Methamphetamine - 1
NCT00267657
Modafinil vs Placebo for the Treatment of Methamphetamine Dependence
NCT00469508
Assessment of Potential Interactions Between Methamphetamine and Bupropion - 1
NCT00040040
Evaluation of Modafinil as a Cocaine Treatment Medication and Interactions With Cocaine - 1
NCT00033046
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Modafinil
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* good physical and mental health
* body mass index between 18 and 30
* if female, using an acceptable method of contraception and are not pregnant
* able to give voluntary informed consent
Exclusion Criteria
18 Years
45 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Drug Abuse (NIDA)
NIH
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Reese Jones, M.D.
Role: PRINCIPAL_INVESTIGATOR
Langley Porter Psychiatric Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
U of CA, San Francisco
San Francisco, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIDA-CPU-0008-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.